C
Sanofi SNY
$48.09 -$0.73-1.50% NASDAQ
Recommendation
Prev Close
$48.09
Volume
3,355
Avg Vol (90D)
2,761,979
Market Cap
$117.88B
Dividend & Yield
$1.60(3.32%)
52-Week Range
$44.62 - $60.12
P/E (TTM)
11.30
EPS (TTM)
$4.25
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
6/12/2025 - MarketBeat
ITM Appoints Annette Breunig as Chief People Officer
10/13/2025 - Globe Newswire
Zacks Research Has Pessimistic View of Sanofi Q1 Earnings
10/13/2025 - MarketBeat
Sanofi Consumer Healthcare CFO Narahari Naidu resigns
10/13/2025 - Business Standard - Markets & Investing
Revvity (RVTY): Assessing Valuation Following Sanofi Alliance for Population-Scale Diabetes Diagnostics Expansion
10/12/2025 - Simply Wall St
Novavax (NVAX) Is Down 11.9% After Sanofi Takes Over EU Marketing of Nuvaxovid Vaccine
10/11/2025 - Simply Wall St
FY2025 EPS Estimates for Sanofi Lifted by Leerink Partnrs
10/11/2025 - MarketBeat
Top Research Reports for Walmart, Sony & Citigroup
10/10/2025 - Zacks Investment Research
Leerink Partnrs Issues Negative Forecast for Sanofi Earnings
10/10/2025 - MarketBeat
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
10/9/2025 - Zacks Investment Research
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
10/9/2025 - Zacks Investment Research
Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study
10/8/2025 - Benzinga
Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy
10/8/2025 - Seeking Alpha - Healthcare
Sanofi price target lowered by EUR 3 at Guggenheim, here's why
10/8/2025 - The Fly
OLD National Bancorp IN Decreases Stock Position in Sanofi $SNY
10/8/2025 - MarketBeat
Bernstein Sticks to Their Buy Rating for Sanofi (SNYNF)
10/8/2025 - TipRanks Financial Blog
galdermas itch ad campaign scratched after sanofi complaint
10/8/2025 - FiercePharma
sanofis 110m radioligand therapy hits response rate goal phase 2 tumor trial
10/8/2025 - FierceBiotech.com - Biotech
Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment
10/8/2025 - Nasdaq News: Markets
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
10/8/2025 - Globe Newswire
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
10/8/2025 - Globe Newswire
How Investors Are Reacting To Teva (TEVA) Shifting Focus From Generics to Innovative Medicines
10/8/2025 - Simply Wall St
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M
10/7/2025 - GuruFocus
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU
10/7/2025 - Seeking Alpha - Healthcare
Analysts Think These Stocks Could More Than Double in Value
5/23/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$146.75B
Total Debt (Q)
$26.17B
Total Liabilities (Q)
$64.22B
Book Value Per Share (Q)
$67.55
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, July 31, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Oct 20 and 24 (est)
Price History
Loading...
Beta
0.18
7-Day Total Return
-4.09%
30-Day Total Return
-2.81%
60-Day Total Return
-0.48%
90-Day Total Return
-2.85%
Year to Date Total Return
2.95%
1-Year Total Return
-9.73%
2-Year Total Return
-6.70%
3-Year Total Return
32.26%
5-Year Total Return
8.41%
52-week Low
Sep 30, 2025 - $44.62
52-week High
Mar 10, 2025 - $60.12
Valuation
Market Cap
$117.88B - Large Cap
Enterprise Value
$126.24B
Price/Sales (TTM)
2.40
Price/Book (Q)
0.71
Dividends and Shares
Shares Outstanding
1.22K
Dividend Per Share (Most Recent)
$1.60
Dividend Per Share (TTM)
$1.60
Corporate Info
Website
www.sanofi.com
Phone Number
33 1 53 77 40 00
Address
46, avenue de la Grande Armée
Paris, 75017
Country
France
Year Founded
1994
Business Description
Sector
--
Industry
--
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines... more
NASDAQ 10/10/2025 4:00PM Eastern Quotes delayed